Skip to main navigation Skip to search Skip to main content

Phase I dose-escalation study of the safety and pharmacokinetics of Atrasentan: an endothelin receptor antagonist for refractory prostate cancer

Translated title of the contribution: Phase I dose-escalation study of the safety and pharmacokinetics of Atrasentan: an endothelin receptor antagonist for refractory prostate cancer
  • B.A. Zonnenberg
  • , G. Groenewegen
  • , T.J. Janus
  • , T.W. Leahy
  • , R.A. Humerickhouse
  • , J.D. Isaacson
  • , R.A. Carr
  • , E.E. Voest

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPhase I dose-escalation study of the safety and pharmacokinetics of Atrasentan: an endothelin receptor antagonist for refractory prostate cancer
Original languageUndefined/Unknown
Pages (from-to)2965-2972
Number of pages8
JournalClinical Cancer Research
Volume9
Publication statusPublished - 2003

Cite this